BioRev
Book a 20-minute walkthrough

Illustrative only

IndicationsAll (10)GeographyUS

Development spend, next 12 months

Planned development spend concentrates on the two Phase III programmes: Heart failure (HFrEF) at 28% and ATTR cardiomyopathy at 22%.

CardiovascularRenalMetabolic

Decision calendar

Portfolio decision calendar 2027 to 2031: the first potential launch is ATTR cardiomyopathy in 2028, followed by Heart failure (HFrEF) in 2029.

  1. ATTR-CMPhase IIIReadout 2027 · submission 2027 · launch 2028
  2. HFrEFPhase IIIReadout 2027 · submission 2028 · launch 2029
  3. IgANPhase IIPhase II readout 2027 · potential launch 2030
  4. HFpEFPhase IIPhase II readout 2028 · potential launch 2031
  5. HCMPhase IIPhase II readout 2029 · potential launch 2031
  6. CKDPhase IIPhase II readout 2029 · Phase III start 2030

Changed this quarter